Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in apoE-/- mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 4, 2007, Pages 841-849

  Davis Jr , Harry R ^a   Hoos, Lizbeth M ^a   Tetzloff, Glen ^a   Maguire, Maureen ^a   Zhu, Li Ji ^a   Graziano, Michael P ^a   Altmann, Scott W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ApoE mice; Atherosclerosis; Cholesterol absorption; Ezetimibe; NPC1L1

Indexed keywords

CELL PROTEIN; CHYLOMICRON; EZETIMIBE; NIEMANN PICK C1 LIKE 1 PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; BRACHIOCEPHALIC TRUNK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MOUSE; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL;

ABSORPTION; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BILE; BRACHIOCEPHALIC TRUNK; CHOLESTEROL; DISEASE PROGRESSION; FEMALE; INTESTINES; LIPOPROTEINS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 34247209263     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000257627.40486.46     Document Type: Article

References (19)

1. Rosenblum S, Huynh T, Afonso A, Davis HR, Yumibe N, Clader JW, Burnett D. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S0-hydroxypropyl]- (4S)-(4-hydroxyphenyl)-2-azetidinone (SCH58235):A designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem. 1998;41:973-980.
2. van Heek M, France C, Compton DS, Mcleod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR. In-vivo mechanism-based discovery of a potent cholesterol absorption inhibitor (SCH58235) through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997;283:157-163.
3. Van Heek M, France C, Compton D, Hoos L, Alton K, Sybertz E, Davis HR. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacology. 2000;129:1748-1754.
4. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption. Science. 2004;303:1089-1240.
5. Davis HR, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund E, Detmers P, Graziano MP, Altmann S. Niemann-Pick C1 Like 1 (NPC1L1) Is the Intestinal Phytosterol and Cholesterol Transporter and a Key Modulator of Whole-body Cholesterol Homeostasis. J Biol Chem. 2004;279:33586-33592.
6. Garcia-Calvo M, Lisnock JM, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, Graziano MP, Hughes M, MacIntyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132-8137.
7. Huff MW, Pollex RL, Hegele RA. NPC1L1: Evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol. 2006;26:2433-2438.
8. Davis HR, Compton D, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice. Arterioscler Thromb Vasc Biol. 2001;21:2032-2038.
9. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse, a decade of progress. Arterioscler Thromb Vasc Biol. 2004;24:1006-1014.
10. van Heek M, Farley C, Compton DS, Hoos LM, Smith-Torhan A, Davis HR. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol. 2003;138:1459-1464.
11. Burrier RE, Smith AA, McGregor DG, Hoos LM, Zilli DL, Davis HR. The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine. J Pharm Exp Ther. 1995;272:156-163.
12. Zhu L, Altmann SW. mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal Biochem. 2005;345:102-109.
13. Salisbury BG, Davis HR, Burrier RE, Burnett DA, Boykow G, Caplen MA, Clemmons AL, Compton DS, Hoos LM, McGregor DG, Schnitzer-Polokoff R, Smith AA, Weig BC, Zilli .L, Clader JW, Sybertz EJ. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH48461. Atherosclerosis. 1995;115:45-63.
14. Woollett LA, Osono Y, Herz J, Dietschy JM. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci U S A. 1995;92:12500-12504.
15. Davis HR, Pula K, Alton KB, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with HMG CoA reductase inhibitors in dogs. Metabolism. 2001;50:1234-1241.
16. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005;280:12710-12720.
17. Willner EL, Tow B, Buhman KK, Wilson M, Sanan DA, Rudel LL, Farese RV Jr. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2003;100:1262-1267.
18. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
19. Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson G. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis. 1999;145:301-308.